[The role of PET in lung cancer staging].
The precise staging of lymph-node and distant metastases is pivotal for the choice of surgical procedures and overall therapy planning for patients with lung cancer. FDG-PET/CT plays a central role in the diagnostic algorithm of patients with potentially curable disease. In patients with histologically proven lung cancer, FDG-PET/CT provides a higher diagnostic accuracy in the staging of lymph-node and distant metastases compared to staging with CT alone. Furthermore, as a whole body examination, FDG-PET/CT may replace further additional examinations. Prospective studies have also shown that the number of unnecessary thoracotomies and mediastinoscopies can be reduced by the inclusion of FDG-PET in the preoperative staging.
Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn.
Florian C
FC
Gärtner
Klinik und Poliklinik für Allgemein-, Viszeral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Bonn.
Jens
J
Buermann
Medizinische Klinik und Poliklinik II - Pneumologie, Universitätsklinikum Bonn.
Dirk
D
Skowasch
Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn.
Hans-Jürgen
HJ
Biersack
Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn.
Markus
M
Essler
D018450:Disease Progression; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000473:pathology; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
D019788:Fluorodeoxyglucose F18